Cited 13 times in
Comparative effectiveness of bevacizumab plus cisplatin-based chemotherapy versus pemetrexed plus cisplatin treatment in East Asian non-squamous non-small cell lung cancer patients applying real-life outcomes
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김주항 | - |
dc.date.accessioned | 2014-12-20T17:34:56Z | - |
dc.date.available | 2014-12-20T17:34:56Z | - |
dc.date.issued | 2011 | - |
dc.identifier.issn | 1743-7555 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/94872 | - |
dc.description.abstract | AIM: To indirectly compare real-life clinical effectiveness of bevacizumab + cisplatin-based therapy from the Safety of Avastin in Lung (SAiL) phase IV clinical trial with published evidence from the phase III clinical trial for pemetrexed + cisplatin among East Asian patients with non-squamous metastatic or recurrent non-small cell lung cancer (NSCLC). METHODS: Survival outcomes were compared between subgroups of East Asian patients receiving treatments of either bevacizumab + cisplatin-based chemotherapy or pemetrexed + cisplatin using a matching-adjusted indirect comparison approach. Patient-level data were used to derive a new group with similar characteristics compared to those reported in a phase III clinical trial evaluating pemetrexed + cisplatin therapy. Exclusions to the SAiL data included those with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 2, those with mixed cell histology, non-East Asians and those who did not receive cisplatin-based chemotherapy. In total 1000 samples of the pre-matched analysis set of the SAiL data were selected that resulted in equal distributions of the ECOG PS and gender matching variables selected and evaluated for a progression-free survival (PFS) outcome. RESULTS: Median PFS was longer for patients treated with bevacizumab-based therapy (7.4 months; 95% confidence interval [CI]: 6.7-8.2) versus pemetrexed + cisplatin (6.4 months; 95% CI N/A) among non-squamous East Asian NSCLC patients. CONCLUSION: The results suggest that East Asian non-squamous NSCLC patients treated with bevacizumab-based therapy have a trend toward improved PFS outcomes compared to those treated with pemetrexed + cisplatin, even after adjusting for differences between the two trial groups. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 34~40 | - |
dc.relation.isPartOf | ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Antibodies, Monoclonal/administration & dosage | - |
dc.subject.MESH | Antibodies, Monoclonal, Humanized | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Bevacizumab | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung/drug therapy* | - |
dc.subject.MESH | Cisplatin/administration & dosage | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Far East | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Glutamates/administration & dosage | - |
dc.subject.MESH | Guanine/administration & dosage | - |
dc.subject.MESH | Guanine/analogs & derivatives | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lung Neoplasms/drug therapy* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Pemetrexed | - |
dc.subject.MESH | Survival Analysis | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Young Adult | - |
dc.title | Comparative effectiveness of bevacizumab plus cisplatin-based chemotherapy versus pemetrexed plus cisplatin treatment in East Asian non-squamous non-small cell lung cancer patients applying real-life outcomes | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Gee-Chen CHANG | - |
dc.contributor.googleauthor | Myung-Ju AHN | - |
dc.contributor.googleauthor | Elaine WRIGHT | - |
dc.contributor.googleauthor | Heung Tae KIM | - |
dc.contributor.googleauthor | Joo-Hang KIM | - |
dc.contributor.googleauthor | Jin Hyoung KANG | - |
dc.contributor.googleauthor | Sang-We KIM | - |
dc.contributor.googleauthor | Steven SHERMAN | - |
dc.contributor.googleauthor | Stefan WALZER | - |
dc.identifier.doi | 10.1111/j.1743-7563.2011.01400.x | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00945 | - |
dc.relation.journalcode | J00257 | - |
dc.identifier.eissn | 1743-7563 | - |
dc.identifier.pmid | 21585706 | - |
dc.identifier.url | http://onlinelibrary.wiley.com/doi/10.1111/j.1743-7563.2011.01400.x/abstract | - |
dc.subject.keyword | antineoplastic combined chemotherapy protocol | - |
dc.subject.keyword | Asia | - |
dc.subject.keyword | bevacizumab | - |
dc.subject.keyword | comparative study | - |
dc.subject.keyword | non‐small cell lung carcinoma | - |
dc.contributor.alternativeName | Kim, Joo Hang | - |
dc.contributor.affiliatedAuthor | Kim, Joo Hang | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 7 | - |
dc.citation.number | Suppl.2 | - |
dc.citation.startPage | 34 | - |
dc.citation.endPage | 40 | - |
dc.identifier.bibliographicCitation | ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol.7(Suppl.2) : 34-40, 2011 | - |
dc.identifier.rimsid | 27816 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.